Predicting the profits from Provenge
A week before the FDA advisory committee meeting on Dendreon’s Provenge, investment analyst Adam Feuerstein predicted that if Provenge is approved it could generate over $100 million in sales in 2008. Feuerstein’s estimate is based on a projected price of $30,000 per year per course of the vaccine. His model assumes increasing numbers of men living with (and dying of) metastatic androgen independent refractory prostate cancer (AIPrC) over the next decade.
(full story…)